Evidence map›Paper›PMID 32753843›Full record

ArticleDrug design, development and therapy2020

The Expression and Therapeutic Potential of Checkpoint Kinase 2 in Laryngeal Squamous Cell Carcinoma.

Ying Tian, Yan Wang, Shan Xu, Chao Guan, Qingfu Zhang, Wei Li

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Drug design, development and therapy, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.2field-weighted citation impact, top 48% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 4 citations in OpenAlex.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 1 institution in 1 country.

Ying TianDepartment of Otorhinolaryngology, The First Affiliated Hospital of China Medical University, Shenyang, People's Republic of China.
Yan WangDepartment of Otorhinolaryngology, The First Affiliated Hospital of China Medical University, Shenyang, People's Republic of China.
Shan XuDepartment of Otorhinolaryngology, The First Affiliated Hospital of China Medical University, Shenyang, People's Republic of China.
Chao GuanDepartment of Otorhinolaryngology, The First Affiliated Hospital of China Medical University, Shenyang, People's Republic of China.
Qingfu ZhangDepartment of Pathology, The First Affiliated Hospital and College of Basic Medical Sciences of China Medical University, Shenyang, People's Republic of China.
Wei LiDepartment of Otorhinolaryngology, The First Affiliated Hospital of China Medical University, Shenyang, People's Republic of China.ORCID 0000-0001-9368-3397
First Hospital of China Medical University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

introductionLaryngeal squamous cell carcinoma (LSCC) is the most common histological subtype of laryngeal cancer. The involved molecular mechanisms and suitable therapeutic targets for LSCC still need to be further investigated. Checkpoint kinase 2 (CHK2) participates in several cellular physiology pathways and plays a role in tumor progression. However, the roles of CHK2 in LSCC remain unclear.

methodsmRNA expression data were obtained from The Cancer Genome Atlas (TCGA) database, and bioinformatic analysis was performed. Western blot and immunohistochemical analyses were conducted to detect protein expression. MTS assays were performed to examine cell growth of LSCC-derived cell lines.

resultsIn the present study, we found that both active form of CHK2 and total CHK2 protein expressions were up-regulated in LSCC tissues. Positive expression of CHK2 was closely associated with advanced clinical features and poor prognosis. Moreover, potential CHK2-involving bioprocesses and signaling pathways were analyzed. In addition, repressed proliferation of LSCC cells was induced by CHK2 inhibitor. DISCUSSION: Taken together, our findings elucidated that CHK2 may act as an oncogenic factor in LSCC, suggesting a potential target for clinical treatment.

Indexed as

AgedAged, 80 and overCarcinoma, Squamous CellCell ProliferationCheckpoint Kinase 2Enzyme InhibitorsFemaleHumansLaryngeal NeoplasmsMaleMiddle AgedRNA, MessengerTumor Cells, CulturedCheckpoint Kinase 2CHEK2 protein, humanEnzyme InhibitorsRNA, MessengerBML-277checkpoint kinase 2laryngeal squamous cell carcinomatumor growth

Identifiers

PMID32753843
PMCPMC7351626
OpenAlexW3039008333

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.